Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alcestobart + Tislelizumab + Bevacizumab + Fluoropyrimidine in Colorectal Cancer
NCT05609370Phase 2Active, not recruiting
- Sponsor
- BeiGene
- Start
- Jan 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of alcestobart in colorectal cancer (CRC) (8 arms), sponsored by BeiGene. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs) and Progression Free Survival up to 11.0 months. Started Jan 2023; status: active, not recruiting.
02
Drugs
alcestobart
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05609370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05609370.